The Launch Ceremony for the First Shipment of Shuangcheng Pharmaceutical's Paclitaxel (Albumin-bound) for Injection to the U.S. Was Successfully Held.2025.5.19
2025-11-18 10:24
The Launch Ceremony for the First Shipment of Shuangcheng Pharmaceutical's Paclitaxel (Albumin-bound) for Injection to the U.S. Was Successfully Held.
After nine years of dormant preparation like a dragon hiding its scales, it finally breaks through the waves and roars to the sky. In May, the Launch Ceremony for the First Shipment of Shuangcheng Pharmaceutical's Paclitaxel for Injection (Albumin-bound) to the U.S. was grandly held at the factory of its holding subsidiary, Ningbo Shuangcheng.
At the ceremony, Dr. LI JIANMING, General Manager of Shuangcheng Pharmaceutical, stated: "This first shipment ceremony is a major milestone for Shuangcheng Pharmaceutical, marking a crucial step in the company's international strategy. Paclitaxel (Albumin-bound) for Injection is a high-difficulty and complex pharmaceutical preparation. Due to the high review requirements of the U.S. FDA for this type of product and the strict GMP production management standards, it is difficult to obtain FDA approval. The approval indicates that the safety and efficacy of the company's Paclitaxel (Albumin-bound) for Injection have reached the level of the original innovator drug, demonstrating the internationally advanced R&D and production capabilities of Shuangcheng Pharmaceutical."
As a high-difficulty generic drug, Paclitaxel (Albumin-bound) for Injection is full of challenges in R&D, production and quality control. However, all employees of Shuangcheng Pharmaceutical have overcome numerous difficulties and successfully launched this high-difficulty anti-tumor drug into the U.S. market, which is truly remarkable. We would like to express our sincere gratitude to everyone for their dedication and efforts in this regard.
Indication: Paclitaxel (Albumin bound) for injection is used as microtubule inhibitor to treat:
Breast cancer that has spread to other parts of the body and has not improved or worsened after treatment with other medications or Breast cancer that recurs within 6 months of adjuvant chemotherapy. Unless there are clinical contraindications, neoadjuvant treatment should include anthracyclines.
Paclitaxel is also used in combination with carboplatin as first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC).
Paclitaxel in combination with gemcitabine is used as first-line treatment for metastatic pancreatic adenocarcinoma.
In the future, Shuangcheng Pharmaceutical will continue to deepen its global market layout, accelerate the process of drug registration and commercialization in regions such as Europe, the United States and emerging markets, and build a Chinese pharmaceutical brand with international competitiveness.
